ArticleFrontiers in immunology2022
Airway Administration of Bacterial Lysate OM-85 Protects Mice Against Respiratory Syncytial Virus Infection.
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Targeting the Gut Microbiota with Pro- and Postbiotics: Emerging Strategies against Alopecia.Probiotics and antimicrobial proteins · 2026Review
- Bacterial-Derived Immunomodulators as a Preventive Strategy for Viral Respiratory Tract Infections and Associated Wheezing or Asthma in Children: A Targeted Narrative Review.Children (Basel, Switzerland) · 2026Review
- Review
- Pathogenesis of various pulmonary diseases by tuning immune response: insight from host-microbial crosstalk.Current research in microbial sciences · 2026Review
- OM-85 and Respiratory Symptoms in Korean Chronic Obstructive Pulmonary Disease: A Multicenter Observational Study.Tuberculosis and respiratory diseases · 2026Article
- Therapeutic and prophylactic effects of Qipian on COPD in mice: the role of lung and gut microbiota.Microbiology spectrum · 2025Article
- Immunomodulatory Effects of PulmonaromPharmaceuticals (Basel, Switzerland) · 2025Article
- Alveolar Macrophages in Viral Respiratory Infections: Sentinels and Saboteurs of Lung Defense.International journal of molecular sciences · 2025Review
- Is There a Role for Immunostimulant Bacterial Lysates in the Management of Respiratory Tract Infection?Biomolecules · 2024Review
- Diverging patterns in innate immunity against respiratory viruses during a lifetime: lessons from the young and the old.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Modeling Human Respiratory Syncytial Virus (RSV) Infection: Recent Contributions and Future Directions Using the Calf Model of Bovine RSV Disease.Journal of immunology (Baltimore, Md. : 1950) · 2023Review
- Interferons as negative regulators of ILC2s in allergic lung inflammation and respiratory viral infections.Journal of molecular medicine (Berlin, Germany) · 2023Review
- From Amish farm dust to bacterial lysates: The long and winding road to protection from allergic disease.Seminars in immunology · 2023Review
- The OM-85 bacterial lysate: a new tool against SARS-CoV-2?Multidisciplinary respiratory medicine · 2023Article
- Emerging role for interferons in respiratory viral infections and childhood asthma.Frontiers in immunology · 2023Article
- Can bacterial lysates be useful in prevention of viral respiratory infections in childhood? The results of experimental OM-85 studies.Frontiers in pediatrics · 2022Review
- A comprehensive perspective on the interaction between gut microbiota and COVID-19 vaccines.Gut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a seasonal pathogen responsible for the highest percentage of viral bronchiolitis in pediatric patients. There are currently no vaccine available and therapeutic methods to mitigate the severity of RSV bronchiolitis are limited. OM-85, an oral standardized bacterial lysate isolated from human respiratory strains and widely used to prevent recurrent infections and/or exacerbations in populations at risk, has been shown to be effective and safe in children and adults. Here, we demonstrate that airway administration of OM-85 in Balb/c mice prior to infection prevents RSV-induced disease, resulting in inhibition of viral replication associated with less perivascular and peribronchial inflammation in the lungs. These protective effects are dose and time-dependent with complete protection using 1mg dose of OM-85 only four times intranasally. Mechanistic insights using this topical route in the airways revealed increased alveolar macrophages, a selective set of tolerogenic DCs, Treg and Th1 expansion in the lung, even in the absence of infection, contributing to a better Th1/Th2 balance and preventing ILC2 recruitment in the airways and associated inflammatory sequelae. OM-85 preventive treatment also improved antiviral response by increasing IFNβ and its responsive genes in the lung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.